AUSTIN, Texas & ROTTERDAM, Netherlands--(BUSINESS WIRE)--Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, and ViroNovative BV today announced that the companies have signed a licensing agreement that gives Luminex worldwide rights to use ViroNovative’s human metapneumovirus (hMPV) intellectual property in the xTAG Respiratory Viral Panel (RVP). Under the terms of the agreement, rights to ViroNovative’s hMPV intellectual property will be extended to Luminex’s distributors and end-user customers around the world.
